Fujian Haixi Pharmaceuticals Co., Ltd. (Stock Code: 2637) announced that on 24 October 2025, it subscribed for HKD200 million in Series 2025-32 Fund Linked Notes issued by Essence Global Investment Limited under a US$1 billion Guaranteed Structured Note Programme. This subscription involves notes with a maturity date of 27 October 2028, linked to Generations Capital Management SP. The interest payable is based on returns from the underlying fund holdings, with a 0.30% per annum management fee deducted upon redemption.

On the same date, the company also subscribed for up to HKD200 million in China Rock Fund SPC. This principal-protected product has an expected annual return rate ranging from 2.5% to 6.0%, investing primarily in short-term, high-quality money market instruments such as U.S. Treasuries with remaining maturity under one year. Redemption can be made at any time, subject to an irrevocable application process.

According to the announcement, these investments aim to maximize the use of available surplus cash, with the Board indicating that the terms and returns align with capital safety and liquidity objectives. Both transactions qualify as discloseable under Chapter 14 of the Listing Rules, requiring notification and announcement but not shareholders’ approval, with company directors concluding that the arrangements are on normal commercial terms and in the interests of shareholders.